Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer

OXFORD, England, April 29, 2013 /PRNewswire/ --

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim

(BI) today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP^® discovery platform.

Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications. Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.

OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.

Christian Rohlff, CEO of OBT, commented: "Selecting the right target is fundamental for the successful development of a first in class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development."

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on delivering innovative and cost-effective first-in-class medicines to fulfil major unmet patient needs in the field of cancer. OBT is developing cutting-edge antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered through its unique OGAP^® proteomic database. OGAP^® represents the world's largest proprietary collections of disease-associated proteins. It contains proteomic data on over 7,500 cancer membrane proteins and proprietary protein disease expression information more than three-quarters of the entire human proteome. Over two million human protein fragments have been sequenced in OGAP^® in 50 different human tissues representing 60 diseases, including 25 forms of cancer.

OBT has access to the most advanced antibody technologies and expertise through its partnerships with Seattle Genetics, BMS (Medarex), Amgen, Alere (formerly Biosite) and BioWa, and through its development alliances with Menarini and Sanofi. These partnerships have enabled OBT to convert its world leading capabilities in the discovery of novel oncology targets into a highly attractive pipeline of therapeutic oncology antibodies.

For further information, please see http://www.OxfordBioTherapeutics.com

OBT Contact Information:

Chief Executive Officer:
       Christian Rohlff, Ph.D.
       +44-(0)1235-861770
       E-mail cr@oxbt.co.uk
       
Media enquiries/Citigate:
       David Dible
       +44-(0)207-638-9571
       E-mail david.dible@citigatedr.co.uk